
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc demonstrated robust revenue growth, with Cell Processing revenue reaching $23.0 million, representing a year-over-year increase of 28%, and total revenue for the second quarter of 2025 hitting $25.4 million, marked by a 29% year-over-year growth. The company has raised its 2025 revenue guidance to a range of $100-103 million, signaling a projected growth of 22-25% compared to the previous year, bolstered by sustained traction in both Cell Processing and evo and Thaw services. Management's expectations of improved adjusted EBITDA margins and reduced net losses further underscore the company's strong financial foundation and growth trajectory within the cell and gene therapy industry.
Bears say
BioLife Solutions Inc. faces several substantial risks, including lower-than-projected growth of its products and services, challenges in securing new customers, and fluctuations in sales due to emerging market dynamics and foreign exchange rates, which collectively contribute to a negative outlook. The company reported a net loss of $15.8 million, significantly higher than the estimated loss of $2.0 million, largely driven by in-process R&D expenses related to the PanTHERA transaction. Additionally, management's revision of FY2025 revenue guidance to $95.0-96.0 million, reflecting a decline of approximately $8 million in expected revenue, raises concerns about the company's growth trajectory, particularly given the reliance on the Cell Processing platform for the majority of revenue.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares